View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Jan. 19 (HealthDay News) -- The largest study linking hormone replacement therapy (HRT) to breast cancer, the Million Women Study (MWS), had flaws in its design and the findings do not satisfy the principles of causation, according to an evidence review published online Jan. 16 in the Journal of Family Planning & Reproductive Health Care.
Samuel Shapiro, Ph.D., of the University of Cape Town in South Africa, and colleagues assessed the evidence for causality for estrogen plus progestogen (E+P) and for unopposed estrogen therapy (ET) in the MWS, using generally accepted causal criteria.
The researchers found that the findings for E+P and for ET did not sufficiently satisfy the criteria for time order, information and detection bias, confounding, statistical stability and strength of correlation, duration-response, internal and external consistency, or biological plausibility, in spite of the massive size of the MWS. The apparent risks reported would have been nullified had detection bias resulted in the identification of 0.3 additional cases of breast cancer in ET users (women aged 50 to 55 years) per 1,000 per year, or 1.2 cases in E+P users.
"HRT may or may not increase the risk of breast cancer, but the MWS did not establish that it does," the authors conclude.
Several authors disclosed financial ties to the manufacturers of products mentioned in the review.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top